Antibodies against viral nucleo-, phospho-, and X protein contribute to serological diagnosis of fatal Borna disease virus 1 infections.
Borna disease virus 1
ELISA
antibodies
diagnostics
encephalitis
encephalopathy
humoral immune response
recombinant protein
zoonosis
Journal
Cell reports. Medicine
ISSN: 2666-3791
Titre abrégé: Cell Rep Med
Pays: United States
ID NLM: 101766894
Informations de publication
Date de publication:
18 01 2022
18 01 2022
Historique:
received:
30
08
2021
revised:
23
11
2021
accepted:
17
12
2021
entrez:
2
2
2022
pubmed:
3
2
2022
medline:
5
3
2022
Statut:
epublish
Résumé
Borna disease virus 1 (BoDV-1) causes rare but often fatal encephalitis in humans. Late diagnosis prohibits an experimental therapeutic approach. Here, we report a recent case of fatal BoDV-1 infection diagnosed on day 12 after hospitalization by detection of BoDV-1 RNA in the cerebrospinal fluid. In a retrospective analysis, we detect BoDV-1 RNA 1 day after hospital admission when the cell count in the cerebrospinal fluid is still normal. We develop a new ELISA using recombinant BoDV-1 nucleoprotein, phosphoprotein, and accessory protein X to detect seroconversion on day 12. Antibody responses are also shown in seven previously confirmed cases. The individual BoDV-1 antibody profiles show variability, but the usage of three different BoDV-1 antigens results in a more sensitive diagnostic tool. Our findings demonstrate that early detection of BoDV-1 RNA in cerebrospinal fluid and the presence of antibodies against at least two different viral antigens contribute to BoDV-1 diagnosis. Physicians in endemic regions should consider BoDV-1 infection in cases of unclear encephalopathy and initiate appropriate diagnostics at an early stage.
Identifiants
pubmed: 35106511
doi: 10.1016/j.xcrm.2021.100499
pii: S2666-3791(21)00376-1
pmc: PMC8784767
doi:
Substances chimiques
Antibodies
0
Nucleoproteins
0
Phosphoproteins
0
Recombinant Proteins
0
Viral Proteins
0
Types de publication
Case Reports
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
100499Informations de copyright
© 2022 The Authors.
Déclaration de conflit d'intérêts
P.S. is an employee of Mikrogen GmbH. E.S. is CEO and a shareholder of Mikrogen GmbH. The other authors declare no competing interests.
Références
N Engl J Med. 2018 Oct 4;379(14):1377-1379
pubmed: 30281984
Emerg Infect Dis. 2021 May;27(5):1371-1379
pubmed: 33900167
Lancet Infect Dis. 2020 Apr;20(4):467-477
pubmed: 31924550
J Clin Microbiol. 2005 Sep;43(9):4551-7
pubmed: 16145106
Antiviral Res. 2017 Jul;143:237-245
pubmed: 28465146
N Engl J Med. 2015 Jul 9;373(2):154-62
pubmed: 26154788
PLoS One. 2014 Apr 03;9(4):e93659
pubmed: 24699636
Acta Neuropathol. 2019 Jun;137(6):1017-1019
pubmed: 30953131
Acta Neuropathol. 2019 Oct;138(4):653-665
pubmed: 31346692
Anal Biochem. 1981 Nov 1;117(2):307-10
pubmed: 6172996
N Engl J Med. 2018 Oct 4;379(14):1375-1377
pubmed: 30281979
PLoS One. 2015 Aug 27;10(8):e0137018
pubmed: 26313904
J Virol. 1999 Sep;73(9):7903-6
pubmed: 10438889
Adv Virus Res. 2020;107:159-222
pubmed: 32711729